NEW YORK (GenomeWeb News) - Agilent Technologies has expanded the National Cancer Institute's access to its microarray technology program, the company said today.
Under the program, NCI extramural researchers can obtain Agilent's microarray technology -- including reagents, catalogs and custom microarrays, instrumentation, and software -- for comparative genomic hybridization, location analysis, and gene expression.
The NCI funds approximately 4,500 research grants each year.
Researchers realize gene-expression data alone is not enough in cancer research, and that complementary microarray applications are necessary, the company said.
Agilent will offer researchers promotional pricing, the company said.
Separately today, Agilent said it wrapped up the sale of its semiconductor products business to Kohlberg Kravis Roberts and Silver Lake Partners for $2.66 billion.
The divestiture includes 6,500 employees and operations in Asia, the United States and Europe.